Ozempic at week 5: what the early weeks actually mean

What did @serenaa1981 actually say?

At week five on semaglutide 0.5mg, this creator described a rough picture: persistent nausea managed with Gravol, dramatic taste changes, "super super lows" in blood sugar, severe vomiting including one episode she described as purging "everything" from the past four weeks, and morning glucose finally hitting single digits. She's managing type 2 diabetes without a family doctor, with her dietitian as the only healthcare touchpoint until January.

That's a lot happening at once. The dose increase to 0.5mg is the standard titration step in the Ozempic protocol, so she's following the prescribed escalation schedule. But several of what she describes as manageable side effects are worth scrutinizing more carefully, because some of them cross into territory that warrants real clinical attention, not just a TikTok comment section.

Does the science back this up?

The nausea and taste changes are well-documented. The vomiting episode she described is more concerning. GLP-1 receptor agonists slow gastric emptying, and this mechanism is central to how they reduce appetite. But prolonged vomiting is not a badge of the drug working harder.

The SUSTAIN-6 trial (Marso et al., 2016, NEJM) and subsequent real-world pharmacovigilance data confirm that gastrointestinal events are the most common reason people discontinue semaglutide. Nausea affects roughly 20% of users at the 0.5mg dose. Severe vomiting lasting days is less common and is associated with dehydration risk, electrolyte imbalance, and in rare cases gastroparesis. A 2023 study in JAMA (Sodhi et al.) flagged a significantly elevated risk of gastroparesis-related diagnoses in GLP-1 users compared to controls. The taste alteration she reports is real: a 2022 paper in Obesity (Izquierdo et al.) documented altered taste perception in semaglutide users, likely linked to central GLP-1 receptor activity in the brain's reward circuitry.

The "super lows" she mentions deserve separate attention entirely.

What did they get wrong (or right)?

She got the nausea narrative mostly right. Gravol (dimenhydrinate) is a reasonable short-term antiemetic and is commonly used to manage GLP-1-induced nausea, though it's not officially indicated for this and the evidence is anecdotal rather than trial-based.

What she gets wrong, or at least dangerously underframes, is the hypoglycemia. Semaglutide alone does not typically cause hypoglycemia in type 2 diabetes. It's glucose-dependent, meaning it stops stimulating insulin when blood sugar drops. "Super super lows" should not be happening on semaglutide monotherapy. If she's also on a sulfonylurea, insulin, or another agent, that combination changes everything. The drug interaction risk is real: the American Diabetes Association Standards of Care (2024) explicitly flags that combining GLP-1 agonists with insulin or sulfonylureas increases hypoglycemia risk and may require dose adjustment of the other agent. She doesn't mention her other medications, which is a significant gap in her self-assessment.

She's also framing severe vomiting as something she waited out, which is understandable given her healthcare access situation, but medically it's not a wait-and-see symptom.

What should you actually know?

The healthcare access issue she raises is real and serious. Newfoundland and Labrador has among the highest rates of unattached patients in Canada, and the structural problem she's describing is not an excuse or laziness. It's a documented public health gap. But it makes the self-monitoring stakes higher, not lower.

A few things people on GLP-1 therapy without close physician oversight should actually know: First, if you're experiencing hypoglycemia on semaglutide, something else is driving it, and that something else needs to be identified. Second, vomiting severe enough to cause multi-day episodes warrants an ER visit even with long wait times, specifically because dehydration plus potential electrolyte disturbances plus an active GLP-1 slowing gastric motility is a combination that can escalate. Third, single-digit morning glucose readings in a previously uncontrolled type 2 diabetic are clinically significant. That's not just "great news," that's data her prescriber needs to see before her January dietitian appointment.

The dietitian is a valuable resource, but titrating semaglutide and managing hypoglycemia risk is outside a dietitian's scope of practice in most Canadian provinces. She needs a physician or nurse practitioner, full stop.